James thanks for the thoughts and responding. I agree with your points. Even though I am very frustrated with the way this stock moves (like everyone else), I got into this with the understanding that I would probably be a holder for 3-5 years.
If I were to provide a rhetorical to the pondering Q's, it would sound similar to your points. For some reason I felt compelled to bring attention to Fispemifine, which is widely accepted now as this companies future, when in my view, the landscape for Testosterone therapy in the future is unknown. The problems with testosterone treatment are just now surfacing, and whether true problems exist, or whether lawyers are Inflating the problems, is still a question in my mind. I have read that high levels of T associated with injections can be the problem, but I also have seen advertisements from law firms that only seek those that have used gels for T replacement. I have read that the gels can remain in the lipid layer of the skin in concentrated levels, and then release to cause testosterone spikes. I find it interesting that in one advertisement for those harmed by T replacement, the law firm didn't even mention the injectable forms of T in their advertisement...only the gels. The FDA will have to try to sort out NDA's for T replacement in this landscape. I'm not sure how that translates for Fispemifjne. I do agree that the method of action provided by Fispemifine may be just what is needed for successful T replacement moving forward. A drug that doesn't shut down the hypothalamus-pituitary-gonadal axis, but rather encourages it's function to produce more T endogenously...and within the safer levels that you refer to, elevating T with Fispemiifne could very well be the billion dollar answer to the questions surrounding T replacement. I do believe it is a very good drug candidate, I am just being a little cautious given the current landscape surrounding T replacement.
As for Femprox, I am very excited to see it being mentioned again. As Eman and you have long asserted, Femprox is not dead. I think it was the appropriate response by the company to take advantage of the timing associated with Flibs approval, to have a press release shopping Femprox. As others have mentioned, a much different drug than Flib, hopefully the end points reached in testing will be of interest to companies wanting to take advantage of the current climate for FSAID.
Couldn't agree more on Vitaros, 2016 or 2017 should reveal it's potential...though I think it's the later.
As for the money, let's hope they can raise it the ways you mention. Not sure my stomach will like the less retail investor friendly methods :)
One last note. The views on the other board have long been interesting, valuable and often entertaining. If I were keeping score and we tallied points on one's viewpoints vs those things that transpire, I would have to say that several that contribute on this board are doing quite well. Part of my pondering Q's on the other board was nothing more than innuendo to hint at that... |
